A novel prognostic model for patients with sarcomatoid renal cell carcinoma

BJU International

Volumn 115, Issue 3, 2015, Pages 405-411

  Zhang, Ben Y ^a   Thompson, R Houston ^a   Lohse, Christine M ^a   Leibovich, Bradley C ^a   Boorjian, Stephen A ^a   Cheville, John C ^a   Costello, Brian A ^a  

^a MAYO CLINIC   (United States)

Author keywords

amount of sarcomatoid differentiation; prognostic model; renal cell carcinoma (RCC); sarcomatoid histology

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGIST; PATIENT HISTORY OF NEPHRECTOMY; PRIMARY TUMOR; RISK ASSESSMENT; SARCOMATOID CARCINOMA; STATISTICAL MODEL; TUMOR NECROSIS; CARCINOMA, RENAL CELL; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM GRADING; PROGNOSIS;

EID: 84922935573     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12781     Document Type: Article

References (22)

1. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A,. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999; 17: 523-528
2. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25: 275-284
3. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004; 28: 435-441
4. Shuch B, Pantuck AJ, Pouliot F, et al. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance. BJU Int 2011; 108: 343-348
5. Abel EJ, Carrasco A, Culp SH, et al. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int 2012; 110: 1742-1746
6. Delahunt B, Egevad L, Montironi R, Srigley JR,. International Society of Urological Pathology (ISUP) consensus conference on renal neoplasia: rationale and organization. Am J Surg Pathol 2013; 37: 1463-1468
7. Conant JL, Peng Z, Evans MF, Naud S, Cooper K,. Sarcomatoid renal cell carcinoma is an example of epithelial-mesenchymal transition. J Clin Pathol 2011; 64: 1088-1092
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124
9. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456
10. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
11. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134
12. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111
13. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428
14. Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27: 235-241
15. Molina AM, Tickoo SK, Ishill N, et al. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 2011; 34: 454-459
16. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP,. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101: 1545-1551
17. Roubaud G, Gross-Goupil M, Wallerand H, de Clermont H, Dilhuydy MS, Ravaud A,. Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. Oncology 2011; 80: 214-218
18. Haas NB, Lin X, Manola J, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2012; 29: 761-767
19. Shuch B, Bratslavsky G, Shih J, et al. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int 2012; 109: 1600-1606
20. Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167: 65-70
21. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Workshop on diagnosis and prognosis of renal cell carcinoma. Rochester, Minnesota, March 21-22, 1997. Cancer 1997; 80: 973-1000
22. Ljungberg B, Alamdari FI, Stenling R, Roos G,. Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol 1999; 36: 565-569